PA5-40416

antibody from Invitrogen Antibodies

Targeting: FGD1 FGDY, ZFYVE3

Western blot

Antibody data

Submit

Validation data

Product number: PA5-40416 - Provider product page
Provider: Invitrogen Antibodies
Product name: FGD1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Peptide sequence: WMAVLGRAGR GDTFCPGPTL SEDREMEEAP VAALGATAEP PESPQTRDKT Sequence homology: Cow: 86%; Dog: 86%; Horse: 79%; Human: 100%; Mouse: 86%; Pig: 86%; Rabbit: 79%; Rat: 86%
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.5 mg/mL
Storage: -20°C, Avoid Freeze/Thaw Cycles

FGD1 protein structure - PA5-40416 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 FGD1 interacts with PTEN to inhibit PTEN phosphates activity in osteosarcoma cells. A, the WCL of 293T cells were subjected to silver staining and mass spectrometry after transfected indicated plasmids. B-C , 293T cells transfected with indicated plasmids was harvested for co-immunoprecipitation. D-E , Western blotting analysis of WCL of U-2OS, MG63 and MNNG/HOS cells. F , a schematic diagram depicting the domain of PTEN. G , Flag-FGD1, Myc-PTEN-C and Myc-PTEN-N were translated in vitro , and the co-immunoprecipitation was performed to evaluate the interaction between the PTEN recombination protein and FGD1. H , a schematic diagram depicting FGD1 interacted with the N-terminal region of PTEN. I , U-2OS, MG63 and MNNG/HOS cells were transfected with indicated constructs. After 72 h, the spend medium of each treatment group were collected for release phosphatase assay. ***, P < 0.001. J , Western blotting analysis of the WCL of osteosarcoma tumor cells (U-2OS, MG63 and MNNG/HOS) after transfected with indicated siRNAs. K , Western blotting analysis of the WCL of osteosarcoma tumor cells (U-2OS, MG63 and MNNG/HOS) after transfected with indicated plasmids.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 FGD1 increases PD-L1 expression in OS cells. A-C, U-2OS, MNNG/HOS and 143b cells were infected with indicated shRNAs. After 72 h, cells were harvested for Western blotting analysis (A), RT-qPCR analysis (B) and flow cytometry assay (C). Date showed as Mean +- SD with three replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.001. D-E , U-2OS, MNNG/HOS and 143b cells were infected with indicated plasmids. After 48 h, cells were harvested for Western blotting analysis (D), and RT-qPCR analysis (E). Date showed as Mean +- SD with three replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.001. F-H , IHC analysis of FGD1 and PD-L1 in osteosarcoma tissue microarray. The typical image of IHC as presented in panel F, the IHC scores of FGD1 or PD-L1 in each osteosarcoma specimens as indicated in panel G, the correlation between FGD1 and PD-L1 as showed in panel H.